Jump to content

European Registry of Hereditary Pancreatitis and Pancreatic Cancer

From Wikipedia, the free encyclopedia
(Redirected from Europac)

The European Registry of Hereditary Pancreatitis and Pancreatic Cancer (EUROPAC) was started by John Neoptolemos and colleagues[1] in 1997 and has become the world’s most extensive study on hereditary pancreatic diseases. It enabled discovery of several genetic characteristics causative for hereditary pancreatitis and familial pancreatic cancer.[2][3][4][5]

Description

[edit]

EUROPAC is based at the Royal Liverpool University Hospital and it is supported by grants from Cancer Research UK, the European Union, the National Institute for Health and Care Research (NIHR), Pancreatic Cancer UK, NHS England, and Cheshire and Merseyside Cancer Alliance.

It maintains a registry of families in whom there is thought to be an increased risk of pancreatic cancer. Studies have shown that an increased risk of cancer is inferred if two or more first-degree relatives have the condition. In addition to the Familial Pancreatic Cancer (FPC) registry, EUROPAC offers screening for early pancreatic cancer on a research basis in those deemed at high risk for the development of the condition. Screening for early pancreatic cancer involves several different blood tests and scans and is usually undertaken from the age of 40 in high-risk individuals.

Patients who have a family history of pancreatic cancer or pancreatitis may be eligible to join the study. Referrals are made via genetic counsellors, GPs, other consultants or directly via email.

The research team based in Liverpool includes Annabelle Boughey (EUROPAC Operations Manager), Paul Thomas (EUROPAC Coordinator) Phil Hopley (clinical research fellow), Professor Christopher Halloran (principal investigator) and Professor William Greenhalf (lead scientist).

References

[edit]
  1. ^ Finch, Margaret D.; Howes, Nathan; Ellis, Ian; Mountford, Roger; Sutton, Robert; Raraty, Michael; Neoptolemos, John P. (1997). "Hereditary Pancreatitis and Familial Pancreatic Cancer". Digestion. 58 (6): 564–569. doi:10.1159/000201502. ISSN 0012-2823. PMID 9438603.
  2. ^ Threadgold, J (2002-05-01). "The N34S mutation of SPINK1 (PSTI) is associated with a familial pattern of idiopathic chronic pancreatitis but does not cause the disease". Gut. 50 (5): 675–681. doi:10.1136/gut.50.5.675. ISSN 0017-5749. PMC 1773194. PMID 11950815.
  3. ^ Howes, Nathan; Lerch, Markus M.; Greenhalf, William; Stocken, Deborah D.; Ellis, Ian; Simon, Peter; Truninger, Kaspar; Ammann, Rudi; Cavallini, Giorgio; Charnley, Richard M.; Uomo, Generoso (March 2004). "Clinical and genetic characteristics of hereditary pancreatitis in Europe". Clinical Gastroenterology and Hepatology. 2 (3): 252–261. doi:10.1016/S1542-3565(04)00013-8. PMID 15017610.
  4. ^ McFaul, C D (2006-02-01). "Anticipation in familial pancreatic cancer". Gut. 55 (2): 252–258. doi:10.1136/gut.2005.065045. ISSN 0017-5749. PMC 1856528. PMID 15972300.
  5. ^ Grocock, C. J.; Rebours, V.; Delhaye, M. N.; Andren-Sandberg, A.; Weiss, F. U.; Mountford, R.; Harcus, M. J.; Niemczyck, E.; Vitone, L. J.; Dodd, S.; Jorgensen, M. T. (2010-03-01). "The variable phenotype of the p.A16V mutation of cationic trypsinogen (PRSS1) in pancreatitis families". Gut. 59 (3): 357–363. doi:10.1136/gut.2009.186817. ISSN 0017-5749. PMID 19951905. S2CID 983450.
[edit]